Featured Research

from universities, journals, and other organizations

The Beginning Of The End Of Flagella: Protein Discovery In Chlamydomonas

Date:
November 24, 2003
Source:
Dartmouth College
Summary:
A new protein discovery sheds light on how chemical information is transported within cells. A group of researchers, which includes Dartmouth Professor of Biological Sciences Roger Sloboda, have found the protein EB1 in Chlamydomonas, a single-celled organism commonly used to study cell biology.

HANOVER, NH – A new protein discovery sheds light on how chemical information is transported within cells. A group of researchers, which includes Dartmouth Professor of Biological Sciences Roger Sloboda, have found the protein EB1 in Chlamydomonas, a single-celled organism commonly used to study cell biology. Previous research has implicated EB1 in the progression of many colon cancers.

Published in the November 11 edition of the journal Current Biology, the research examined the chemical motors that power events in flagella, antenna-like structures on some cells. Specifically, the research focused on intraflagellar transport (IFT), the process where proteins required for flagellar growth and maintenance move within the flagella. The discovery of the protein EB1 at the tip of the flagella on Chlamydomonas furthers investigations into the role the protein plays in flagellar function and perhaps in regulating IFT itself.

"Particles move out to the tip of the flagella, turn around, and then move back to the base," says Sloboda, who conducted this research in Joel Rosenbaum's laboratory at Yale University while on sabbatical last year. "The only change in speed or direction occurs when the particles reach the tip. Now we think EB1 might play a role in controlling the molecular transport system responsible for IFT when the particles reach the tip. This finding will help us get a handle on what's going on at the tip of the flagellum."

The flagella beat rhythmically, moving the organism, and are made of nine double strands of microtubules and a central pair. According to Sloboda, similar IFT phenomena also take place in rod and cone cells of the human retina, in human kidney cells, and in nerve cells.

To determine where EB1 occurs in Chlamydomonas cells, the researchers cloned and sequenced the protein to make antibodies specific for EB1. The researchers found that the antibodies bound to the flagella tips, indicating that EB1 stays at the tip, and does not move along the length of the flagella.

"This unexpected observation led to the paper being featured on the cover of the journal," says Sloboda. "It was a great result, because now we know more about the structure of the flagellar tip due to the presence of EB1. Using EB1 as bait, we can move on to fish out other proteins that associate with EB1 and learn how together these proteins are involved in tip structure and function and the process of IFT. Hopefully, our work will inform others working on colon cancer, kidney disease, vision, and central nervous system disorders such as Alzheimer's and Lou Gehrig's diseases."

The other authors on the paper include Lotte Pedersen, a postdoctoral fellow at Yale University; Stefan Geimer, then a postdoctoral fellow at Yale University and now at the Institut Universitδt zu Kφln in Cologne, Germany; and Joel Rosenbaum, Professor of Molecular, Cellular, and Developmental Biology at Yale University.

The study was funded by the National Institutes of Health, a fellowship from the Deutsche Forschungsgemeinschaft, and the Ira Allen Eastman (Class of 1829) Professorship at Dartmouth, which was established in 1910 through a gift to the College by his widow, Jane Eastman.


Story Source:

The above story is based on materials provided by Dartmouth College. Note: Materials may be edited for content and length.


Cite This Page:

Dartmouth College. "The Beginning Of The End Of Flagella: Protein Discovery In Chlamydomonas." ScienceDaily. ScienceDaily, 24 November 2003. <www.sciencedaily.com/releases/2003/11/031121071524.htm>.
Dartmouth College. (2003, November 24). The Beginning Of The End Of Flagella: Protein Discovery In Chlamydomonas. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2003/11/031121071524.htm
Dartmouth College. "The Beginning Of The End Of Flagella: Protein Discovery In Chlamydomonas." ScienceDaily. www.sciencedaily.com/releases/2003/11/031121071524.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins